Comparison of Antiplatelet Effect of Ticagrelor vs Tirofiban in Patients With Non-ST Elevation Acute Coronary Syndrome

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT01660373

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01660373
Other papers using this trial's data
  • Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial Thrombosis and haemostasis, 2016-01 DOI, PubMed 26581884

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01660373. Randomized; no masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2013-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Antiplatelet Effect of Ticagrelor vs Tirofiban in Patients With Non-ST Elevation Acute Coronary Syndrome
Acronym
TE-CLOT
Condition
Non-ST Segment Elevation Acute Coronary Syndrome
Intervention (Drug)
Tirofiban
Intervention (Drug)
Ticagrelor
Lead sponsor
Pusan National University Yangsan Hospital (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct01660373
Content hash
0d971a0e81010980c8c3ec984fb68ac236e47ad5849d102164be2135dcca09b6